IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
SANFILIPPO JOHN B & SON INC vs Phathom Pharmaceuticals, Inc. — Side-by-side quantitative comparison
Based on our 6-factor quantitative model, SANFILIPPO JOHN B & SON INC (JBSS) is the stronger stock with a composite score of 64.5/100 and a Hold rating, compared to Phathom Pharmaceuticals, Inc. (PHAT) at 43.1/100 (Reduce). JBSS ranks #312 in our universe versus #3107 for PHAT, giving it an edge of 21.4 points across quality, value, momentum, investment, stability, and short interest factors.
For the Quality factor — which measures profitability and business quality through metrics like ROE, gross margins, and capital efficiency — JBSS leads at 70/100, while PHAT trails at 46/100 (JBSS: 70/100, PHAT: 46/100). The 24-point gap indicates a meaningful difference in quality characteristics between these stocks.
For the Value factor — which evaluates whether a stock is cheap or expensive relative to its earnings, book value, and cash flows — JBSS leads at 75/100, while PHAT trails at 45/100 (JBSS: 75/100, PHAT: 45/100). The 31-point gap indicates a meaningful difference in value characteristics between these stocks.
On the Momentum factor, which captures price trends and institutional sentiment over the trailing 3-12 months, these stocks are closely matched (PHAT: 60/100, JBSS: 56/100). The narrow 3-point spread suggests similar momentum profiles, so this factor alone is unlikely to be a decisive differentiator.
For the Investment factor — which assesses capital allocation quality including reinvestment rates and asset growth — JBSS leads at 33/100, while PHAT trails at 22/100 (JBSS: 33/100, PHAT: 22/100). The 11-point gap indicates a meaningful difference in investment characteristics between these stocks.
For the Stability factor — which measures financial health through leverage ratios and price volatility — JBSS leads at 88/100, while PHAT trails at 31/100 (JBSS: 88/100, PHAT: 31/100). The 57-point gap indicates a meaningful difference in stability characteristics between these stocks.
For the Short Interest factor — which tracks institutional bearish positioning and potential risk from elevated short selling — JBSS leads at 49/100, while PHAT trails at 15/100 (JBSS: 49/100, PHAT: 15/100). The 34-point gap indicates a meaningful difference in short interest characteristics between these stocks.
Based on our 6-factor model, SANFILIPPO JOHN B & SON INC (JBSS) is utilizing a stronger overall profile than PHAT, with a Composite Score of 65 vs 43. This represents a significant advantage. JBSS dominates specifically in Stability (+57 points) and Short Interest, making it the clear quantitative winner.
| Overall Rating | ||
| Composite Score | 65 | 43 |
| Rank | #312 | #3,107 |
| Stars | 3 / 5 | 2 / 5 |
| Action | Hold | Reduce |
| Factor Scores | ||
| Quality | 70 | 46 |
| Value | 75 | 45 |
| Momentum | 56 | 60 |
| Stability | 88 | 31 |
| Investment | 33 | 22 |
| Short Interest | 49 | 15 |
| Valuation | ||
| P/E Ratio | 11.71 | — |
| P/B Ratio | 2.27 | — |
| P/S Ratio | 0.67 | 4.22 |
| EV/EBITDA | 6.32 | — |
| Dividend Yield | 3.5% | 0.0% |
| Profitability | ||
| ROE | 18.9% | 90.1% |
| ROA | 10.8% | -28.4% |
| Gross Margin | 18.8% | 87.5% |
| Operating Margin | 8.3% | -30.9% |
| Net Margin | 5.7% | -60.6% |
| Growth & Risk | ||
| Revenue Growth | 4.5% | 202.7% |
| Debt/Equity | 11.00 | — |
| Beta | 0.13 | 1.37 |
| Market | ||
| Market Cap | $841M | $835M |
Based on our 6-factor quantitative model, JBSS currently has the higher composite score (64.5/100, Hold) and ranks #312 in our universe. However, the "better" stock depends on your investment goals, risk tolerance, and time horizon. We recommend reviewing the full factor breakdown above before making a decision.
Our comparison analyzes six quantitative factors: Quality (profitability and business strength, 30% weight), Momentum (price trends, 25%), Value (valuation attractiveness, 15%), Investment (capital allocation, 10%), Stability (financial health, 10%), and Short Interest (institutional positioning, 10%). Each factor is scored 0-100 and combined into a composite score.
JBSS has the higher value score at 75/100 compared to PHAT at 45/100. A higher value score indicates the stock trades at a more attractive valuation relative to its earnings, book value, and cash flows.
Our stock rankings and comparisons are updated daily using the latest available market data, financial statements, and price information. Factor scores reflect the most recent quarterly filings and trailing price data.